Actions other than smooth muscle relaxation may play a role in the protective effects of formoterol on the allergen-induced late asthmatic reaction

Pulmonary Pharmacology and Therapeutics

Volumn 15, Issue 4, 2002, Pages 399-406

  Brusasco, V ^a   Crimi, E ^a   Gherson, G ^b   Nardelli, R ^b   Oldani, V ^c   Francucci, B ^c   Della Cioppa, G ^d   Senn, S ^e   Fabbri, L M ^f  

^a UNIVERSITY OF GENOA   (Italy)

^b Respiratory Phisiopathology Unit   (Italy)

^c Medical Department   (Italy)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF FERRARA   (Italy)

Author keywords

Allergen challenge; Allergic asthma; Bronchodilator agents; Formoterol; Late asthmatic reaction; 2 Adrenoceptor agonists

Indexed keywords

ALLERGEN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; FORMOTEROL FUMARATE; METHACHOLINE; PLACEBO; SODIUM CHLORIDE;

ADOLESCENT; ADULT; ALLERGIC ASTHMA; ARTICLE; BREATHING MUSCLE; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRY POWDER; FACTORIAL ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOOTH MUSCLE RELAXATION;

EID: 0036385625     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.2002.0366     Document Type: Article

References (30)

1. O'Byrne P M, Dolovich J, Hargreave F E. The late asthmatic response. Am Rev Respir Dis 1987; 136: 741-751.
2. Lemanske R F, Kaliner M A. Late phase allergic reactions. In: Middleton E Jr, Reed C E, Ellis E F, Adkinson N F, Yuninger J W, Busse W W, eds. Allergy: principles and practice, 4th edn, St Louis: Mosby Yearbook, 1993; 320-361.
3. Cockroft D W, Murdock K Y. Comparative effects of inhaled salbutamol, sodium cromoglycate and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 1987; 79: 734-740.
4. Twentyman O P, Finnerty J P, Harris A, Palmer J, Holgate S T. Protection against allergen-induced asthma by salmeterol. Lancet 1990; 336: 1338-1342.
5. Wong B J, Dolovich J, Ramsdale E H, O'Byrne P, Gontovnick L, Denburg J A, Hargreave F E. Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. Am Rev Respir Dis 1992; 146: 1156-1160.
6. 2-agonist. J Allergy Clin Immunol 1992; 89: 844-849.
7. Pedersen B, Dahl R, Larsen B B, Venge P. The effect of salmeterol on the early- and late- phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X. Allergy 1993; 48: 377-382.
8. Pizzichini M M, Kidney J C, Wong B J O, Morris M M, Efthimiadis A, Dolovich J, Hargreave F E. Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses. Eur Respir J 1996; 9: 449-455.
9. Dente F L, Bancalari L, Bacci E, Bartoli M L, Carnevali S, Cianchetti S, Di Franco A, Giannini D, Vagaggini B, Testi R, Paggiaro P L. Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects. Thorax 1999; 54: 622-624.
10. Bolton P B, Lefevre P, McDonald D M. Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways. Am J Respir Crit Care Med 1997; 155: 1428-1435.
11. National Asthma Education and Prevention Program Expert Panel. Expert Panel No.2: Guidelines to the Diagnosis and Management of Asthma. National Heart and Blood Institute, Bethesda, MD. NIH Publication No. 97-4051, 1997.
12. Quanjer Ph H, Tammeling G J, Cotes J E, Pedersen O F, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flows. Report working party. Standardization of lung function tests. European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J 1993; 6(Suppl 16): 5s-40s.
13. Freeman P R. The performance of the two-stage analysis of two-treatment, two-period cross-over trials. Stat Med 1989; 8: 1421-1432.
14. Senn S. Cross-over trials in clinical research. Chichester, England: John Wiley & Sons Ltd, 1993.
15. Cartier A, Thomson N C, Frith P A, Roberts R, Hargreave F E. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic reaction and change in arway caliber. J Allergy Clin Immunol 1982; 70: 170-177.
16. Crimi E, Brancatisano M, Villa G, Brusasco V. Dual asthmatic reaction to inhaled Dermatophagoides pteronyssinus: frequency, reproducibility and antagonism by cromolyn sodium. Ann Allergy 1986; 56: 183-186.
17. Senn S J, Hildebrand H. Cross-over trials, degrees of freedom, the carryover problem and its dual. Stat Med 1991; 10: 1361-1374.
18. Senn S J. The use of baselines in clinical trials of bronchodilators. Stat Med 1989; 8: 1339-1350.
19. Senn S J, Auclair P. The graphical representation of clinical trials with particular reference to measurements over time. Stat Med 1990; 9: 1287-1302.
20. Rabe K F, Jorres R, Noak D, Behr N, Magnussen H. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993; 147: 1436-1441.
21. Yates D H, Sussman H S, Shaw M J, Barnes P J, Chung K F. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 1995; 152: 1170-1174.
22. Van Noord J A, Smeets J J, Raaijmakers J A M, Bommer A M, Maesen F P V. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9: 1684-1688.
23. Torphy T J, Rinard G A, Rietow M G, Mayer G E. Functional antagonism in canine tracheal smooth muscle: inhibition by methacholine of the mechanical and biochemical responses to isoproterenol. J Pharmacol Exp Ther 1983; 227: 694-699.
24. Robertson D, Kerigan A T, Hargreave F E, Chalmers R, Dolovich J. Late asthmatic responses induced by ragweed pollen allergen. J Allergy Clin Immunol 1974; 54: 244-254.
25. Hargreave F E, Dolovich J, Robertson G, Kerigan A T. The late asthmatic response. Can Med Assoc J 1974; 110: 415-424.
26. MacIntyre D, Boyd G. Factors influencing the occurrence of a late reaction to allergen challenge in atopic asthmatics. Clin Allergy 1984; 14: 311-317.
27. Nightingale J A, Rogers D F, Barnes P J. Differential effect of formoterol on adenosine monophosphate and histamine reactivity. Am J Respir Crit Care Med 1999; 159: 1786-1790.
28. Wallin A, Sandström, Söderberg M, Howarth P, Lundbäck B, Della Cioppa G, Wilson S, Judd M, Djukanovic, Holgate S, Linberg A, Larssen L. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1998; 158: 79-86.
29. British Asthma Guidelines Co-ordinating Committee. British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52(Suppl): S1-S24.
30. Global initiative for asthma. Global strategy for asthma management and prevention. WHO/NHLBI report. NIH publication 95-3659.